Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Miller T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 328:1002.
Coiffier B. (1995) Fourteen years of high-dose CHOP (ACVB regimen): Preliminary conclusions about the treatment of aggressive-lymphoma patients. Annals of Oncology 6:211.
Shipp M., Harrington D.P. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine , for the International non-Hodgkin's lymphoma prognostic factors project.; 329:987.
Goldie J.H., Coldman A.J. (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63:1727.
Goldie J.H., Coldman A.J., Gudanskus G.A. (1982) Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 66:439.
Klimo P., Connors J.M. (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Annals of Internal Medicine 102:596.
Longo D.L., de Vita V.T., Duffey P.L., Wesley M.N., Ihdi D.C., Hublard S.M., Gillion M., Jaffe E.S., Cossman J., Fisher R.I., Young R.C. (1991) Superiority of ProMACE CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomised trial. Journal of Clinical Oncology 9:25.
Coiffier B., Gisselbrecht C., Herbrecht R., Tilly H., Bosly A., Brousse N. (1989) LNH-84 regimen: A multi-centre study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. Journal of Clinical Oncology 7:1018.
Cabanillas F., Hagemeister F.B., McLaughlin P., Salvador P., Velasquez W.S., Riggs S., Freireich F.J. (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology 5:407.
Herbrecht R., Coiffier B., Tilly H. (1989) Mitoxantrone, Ifosfamide and Etoposide (MIV) in aggressive lymphomas failing after treatment with the LNH-87 regimen. Proc ASCO 960 A.
Bosly A., Coiffier B., Gisselbrecht C., Tilly H., Auzanneau G., Andrien F., Herbrecht R., Legros M., Devaux Y., Jaubert J., Pignon G., Michaux J.L., Humblet Y., Dupriez B., Thyss A., Lederlin P. (1992) Bone-marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen. Journal of Clinical Oncology 10:1615.
(1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer , Non-Hodgkin's Lymphoma Pathologic Classification Project; 49:2112.
Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group (ECOG). American Journal of Clinical Oncology 5:649.
Carbone P.P., Kaplan H.S., Musshoff K. (1971) Report of the Committee on Hodgkin's Disease Staging. Cancer Research 31:1860.
Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddeman W., Castellino R., Harris N.L., Armitage R., Canellos G.P. (1999) Report of an international workshop to standardise response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology 17:1244.
Kaplan E., Meier P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistics Association 53:457.
Cox D.R., Oakes D. (1984) Analysis of survival data., Chapman & Hall, New York NY; .
Velasquez W.S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jaganath S., Hagemeister F.B., Redman J.R., Swan F., Barlogie B. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP). Blood 71:117.
Somers R., Carde P., Thomas J., Tirelli U., Keuning J.J., Bron D., Delmer A., de Bock R., De Wolf-Peeters C., van Glabbeke M., Duez N. (1994) EORTC study of non-Hodgkin's lymphoma: Phase III study comparing CHVm P-VB and PROMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Annals of Oncology 5 S(2).
Köppler H., Pflüger K.H., Eschenbach I., Pfab R., Birkmann J., Zeller W., Holle R., Steinhauer U.E., Gropp C., Dehl S., Lennert K., Parwaresch M.R., Kuhn H., Drings P., Grossmann H.H., Khoury M., Schubotz R., Havemann K. (1994) Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: Treatment results and prognostic factor analysis in a multi-centre trial. Annals of Oncology 5:49.
Cameron D.A., White J.M., Proctor S.J., Prescott R.J., Leonard R.C., Angus B., Cook M.K., Dawes P.J., Dawson A.A., Evans R.G., Galloway M.J., Harris A.L., Heppleston A., Horne C.H., Krajewski A.S., Lennard A.L., Lessells H.H., MacGillivray J.B., Mackie M.J., Parker A.C., Roberts J.T., Taylor P.R., Thompson W.D. (1997) CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. European Journal of Cancer 33:1195.